Research programme: multiple sclerosis therapy - Androclus Therapeutics

Drug Profile

Research programme: multiple sclerosis therapy - Androclus Therapeutics

Alternative Names: AT-008

Latest Information Update: 10 Mar 2011

Price : $50

At a glance

  • Originator Androclus Therapeutics
  • Class Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 20 Sep 2006 This programme is still in active development
  • 22 Jun 2005 This programme is still in active development - (BIO-2005)
  • 02 Jul 2004 Preclinical trials in Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top